We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+9.51%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$353M
AUM Growth
-$9.78M
Cap. Flow
-$37.3M
Cap. Flow %
-10.55%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$31.3M
2
ANTH
Anthera Pharmaceuticals, Inc.
ANTH
+$5.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$314M 88.77%
3,952,078
-430,686
-10% -$31.3M
AGRX
2
DELISTED
Agile Therapeutics
AGRX
$28.9M 8.17%
2,531
– –
IMDZ
3
DELISTED
Immune Design Corp.
IMDZ
$10.8M 3.06%
1,962,720
– –
ANTH
4
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-237,500
Closed -$5.99M

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q4 2016 Portfolio in Review

As of Q4 2016, ProQuest Associates IV held 4 positions worth $353M, down 2.7% from $363M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV withdrew a net $37.3M in Q4 2016, closing 1 position and reducing 1 holding. Its most notable exit was Anthera Pharmaceuticals, Inc., an estimated $5.99M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's biggest Q4 2016 reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $31.3M.
  • ProQuest Associates IV fully exited Anthera Pharmaceuticals, Inc. in Q4 2016, selling an estimated $5.99M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $353M portfolio in Q4 2016.
  • ProQuest Associates IV opened 0 new positions and closed 1 in Q4 2016.
  • ProQuest Associates IV's portfolio value fell 2.7% quarter-over-quarter to $353M.

Based on ProQuest Associates IV's 13F filing for Q4 2016, filed 14 Feb 2017.